Dassault bets $2bn on ArisGlobal to fend off AI threat to core business
The French software group is buying a US drug-safety firm to integrate AI into its virtual-twin platform, hoping to calm investor fears that new AI models will render its core technology obsolete.
Dassault Systèmes will pay up to $2 billion for ArisGlobal, a US maker of drug-safety and regulatory software. The French company will hand over $1.8 billion in cash to Swedish private-equity owner Nordic Capital, with another $200 million tied to future AI revenue. The deal marks Dassault’s first major acquisition since it pushed out its chairman in February.
The purchase is a defensive manoeuvre by a European software giant trying to buy its way out of the AI disruption trap. Like SAP and Adobe, Dassault is acquiring external AI capabilities rather than building them from scratch. Investors initially welcomed the move, sending shares up about 5% on Thursday, though the stock remains down roughly a quarter for the year.
Dassault’s anxiety stems from the rise of "world models," a new wave of artificial intelligence that can understand the physical world without needing the detailed digital copies—virtual twins—that form Dassault’s core business. The company uses these twins to help 390,000 customers design everything from aircraft to human bodies.
ArisGlobal processes more than 12 million patient safety reports annually for over 200 customers, including half of the world’s 50 largest drugmakers. Its NavaX system uses generative AI to automate the heavily manual work of drug-safety monitoring, cutting the workload by more than 30%. The broader compliance software market could be worth $7.5 billion by 2030, with ArisGlobal expecting about $175 million in revenue for 2026.
Awkwardly, Dassault is doubling down on the very division dragging down its financial results. Life-sciences revenue fell 4% in the second quarter and 12% in the first. Its last major health-sector acquisition, the 2019 purchase of Medidata, has underwhelmed investors. Chief executive Pascal Daloz is now betting that fusing ArisGlobal’s real-world patient data with Dassault’s virtual models will finally turn the laggard into a growth engine.
“Life Sciences is entering a new era of innovation, driven by AI and the shift to precision medicine,” Daloz said. ArisGlobal chief executive Aman Wasan was more direct: “The future of Life Sciences will not be built on better software. It will be built on connected intelligence.” The deal is expected to close in the second half of 2026, pending regulatory approval, leaving Dassault to prove that this $2 billion wager can actually protect its twin-makers from the AI avalanche.
